Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rose

Showing results (261-270 of 277) with videos related to

Pageof 28
Sort By:
BMJ Open|March 29, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort studySoumaya Labidi, Nicholas Meti, Reeta Barua, et al.
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Environmental Pollution (Barking, Essex : 1987)|April 5, 2011
Open Air Laboratories (OPAL): a community-driven research programmeL Davies, J N B Bell, J Bone, et al.
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
JCO Precision Oncology|January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic CancersMatthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
NMR in Biomedicine|January 18, 2022
Development of a cardiovascular magnetic resonance-compatible large animal isolated heart model for direct comparison of beating and arrested heartsAndrew D Scott, Tim Jackson, Zohya Khalique, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Molecular Cancer Therapeutics|February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast CancerSathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Pageof 28

Showing results (261-270 of 277) with videos related to

Sort By:
Pageof 28
BMJ Open|March 29, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort studySoumaya Labidi, Nicholas Meti, Reeta Barua, et al.
Cell Death & Disease|May 6, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayFeiyang Cai, Fan Huang, Christophe Goncalves, et al.
Environmental Pollution (Barking, Essex : 1987)|April 5, 2011
Open Air Laboratories (OPAL): a community-driven research programmeL Davies, J N B Bell, J Bone, et al.
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
JCO Precision Oncology|January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic CancersMatthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
NMR in Biomedicine|January 18, 2022
Development of a cardiovascular magnetic resonance-compatible large animal isolated heart model for direct comparison of beating and arrested heartsAndrew D Scott, Tim Jackson, Zohya Khalique, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Molecular Cancer Therapeutics|February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast CancerSathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Pageof 28